Clinical Technology

Adult Immunization

MASLD/MASH

Hepatitis

Hepatology

Pediatric Immunization

Colorectal Cancer

Renal Cancer

Lung Cancer

Melanoma

Skin cancer

Prostate Cancer

Breast Cancer

Cervical Cancer

Screening

PTSD

Psychosis

Panic Disorder  

Anxiety

Eating Disorders

Depression

Substance-related Disorders

ADHD

Psychiatry 

Food Allergies

Anaphylaxis

Seasonal Allergies

Allergy

Osteoporosis

Menopause

Pregnancy and Birth

Women's Health

Heart Failure

Atrial Fibrillation

Lipid disorders

Hypertension

Cardiology

Pediatrics

Psoriasis

Rosacea

Atopic Dermatitis

Dermatology

Adrenal Disorders

Thyroid Disorders 

Diabetes

Endocrinology 

Fibromyalgia

Pain Management

GERD

C Difficile Infection

Celiac disease

Irritable Bowel Syndrome 

Inflammatory Bowel Disease

Gastroenterology

Coronavirus

Hepatitis C

Influenza

HIV AIDS

Pneumonia

Sexually transmitted infections

Infectious Disease

Obesity Medicine

Psoriatic arthritis

Lupus

Rheumatoid Arthritis

Osteoarthritis

Gout

Rheumatology

Chronic Kidney Disease

Nephrology

Epilepsy

Cerebrovascular Diseases

Parkinson Disease

Alzheimer Disease/Dementia

Mental Health

Headache

Migraine

Sleep Disorders

Neurology

Pulmonary hypertension

Interstitial lung disease

Asthma

Cystic Fibrosis

COPD

Pulmonology

News

All News

Editorial Podcasts

Practice Management

Video Interviews

Media

Around the Practice

Between the Lines

ConsultantLive

Frontline Insights

Institutional Insights

Primary View

Provider Toolkits

Screening Series

Conferences

Conference Coverage

Conference Listing

Product Theater Recaps

Resources

Interactive Posters

Product Profile

Publications

Subscribe

CE/CME

Patient Care Online offers clinical news and resources for primary care clinicians, focusing on disease states, guidelines, and trends to improve care.

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online – Primary Care News and Clinical Resources

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

Atopic Dermatitis Provider Toolkit

Adult Immunization Provider Toolkit

Dermatology Hot Topics

1rem

Clinical Topics

Topics

Articles

Greater awareness of mental health issues such as these, along with screening for diseases and providing appropriate treatment, may improve symptom control.

Depression, Anxiety May Coexist With Persistent Rhinosinusitis

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps 

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

Pilot Trial Challenges Routine Steroid Use After Pediatric Anaphylaxis ED Discharge

A single dose of neffy was effective in nearly 90% of patients treated for  anaphylactic reactions during oral food challenge and allergen immunotherapy. 

Real-World Data Support Effectiveness of Neffy (epinephrine nasal spray) for Acute Treatment of Anaphylaxis

Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say. 

Intranasal Epinephrine Should Be Prescribed with Confidence, Editorial Encourages

Neffy, a needle-free epinephrine nasal spray, showed promise as a safe alternative for treating anaphylaxis in children with food allergies in a phase 3 trial. 

Needle-Free Epinephrine Nasal Spray Shows Promise in Pediatric Food Allergy Anaphylaxis

Tezepelumab, a thymic stromal lymphopoietin antagonist, 

by the FDA in December 2021 (Tezspire) as add-on maintenance therapy for patients with severe asthma whose symptoms remain uncontrolled on guideline-recommended therapy. Approval was based on findings from the phase 3 

In a presentation at the annual American Academy of Asthma, Allergy, & Immunology meeting, Tara Carr, MD, presented results of a 

 of NAVIGATOR data that assesed the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled 

 comorbidities. Carr spoke with Patient Care Online about the analysis and implications for primary care practice.

is associate professor of medicine and otolaryngology, director, Adult Allergy Program and director, Allergy & Immunology Fellowship Program, Asthma and Airway Disease Research Center, at the University of Arizona College of Medicine in Tucson, Arizona. 

Videos

Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.   

Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities 

Allergy

Latest News

More News